▶ 調査レポート

緑内障治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬剤クラス別(プロスタグランジン、ベータブロッカー、併用薬、アルファ作用薬、炭酸脱水酵素阻害薬、コリン作用薬)、エンドユーザー別(病院、眼科医院、通院外科診療所)

• 英文タイトル:Glaucoma Therapeutics Market (Drug Class - Prostaglandins, Beta Blockers, Combined Medication, Alpha Agonist, Carbonic Anhydrase Inhibitors, and Cholinergic; End User - Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2024

Transparency Market Researchが調査・発行した産業分析レポートです。緑内障治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬剤クラス別(プロスタグランジン、ベータブロッカー、併用薬、アルファ作用薬、炭酸脱水酵素阻害薬、コリン作用薬)、エンドユーザー別(病院、眼科医院、通院外科診療所) / Glaucoma Therapeutics Market (Drug Class - Prostaglandins, Beta Blockers, Combined Medication, Alpha Agonist, Carbonic Anhydrase Inhibitors, and Cholinergic; End User - Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2024 / TPM-B05051資料のイメージです。• レポートコード:TPM-B05051
• 出版社/出版日:Transparency Market Research / 2018年4月25日
• レポート形態:英文、PDF、160ページ
• 納品方法:Eメール
• 産業分類:Pharmaceutical
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、緑内障治療薬の世界市場について調べ、緑内障治療薬の世界規模、市場動向、市場環境、薬剤クラス別(プロスタグランジン、ベータブロッカー、併用薬、アルファ作用薬、炭酸脱水酵素阻害薬、コリン作用薬)分析、エンドユーザー別(病院、眼科医院、通院外科診療所)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、バリューチェーン分析、価格動向分析、供給・需要シナリオ、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・緑内障治療薬の世界市場動向
・緑内障治療薬の世界市場環境
・緑内障治療薬のバリューチェーン分析
・緑内障治療薬の価格動向分析
・緑内障治療薬の供給・需要シナリオ
・緑内障治療薬の世界市場規模
・緑内障治療薬の世界市場規模:薬剤クラス別(プロスタグランジン、ベータブロッカー、併用薬、アルファ作用薬、炭酸脱水酵素阻害薬、コリン作用薬)
・緑内障治療薬の世界市場規模:エンドユーザー別(病院、眼科医院、通院外科診療所)
・緑内障治療薬の世界市場:地域別市場規模・分析
・緑内障治療薬の北米市場規模・予測
・緑内障治療薬のアメリカ市場規模・予測
・緑内障治療薬の中南米市場規模・予測
・緑内障治療薬のヨーロッパ市場規模・予測
・緑内障治療薬のアジア市場規模・予測
・緑内障治療薬の日本市場規模・予測
・緑内障治療薬の中国市場規模・予測
・緑内障治療薬のインド市場規模・予測
・緑内障治療薬の中東市場規模・予測
・緑内障治療薬のアフリカ市場規模・予測
・競争状況・関連企業情報

Glaucoma Therapeutics Market: Overview

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma starts with topical eye drops belonging to the class of prostaglandins, beta blockers, alpha agonist, combined medication, carbonic anhydrase inhibitor and cholinergic. Administration of these eye drops reduces the production of the fluid inside eyes thereby reducing the intraocular pressure. Using topical eye drops is an alternative for surgery or delays the surgical procedure. This report analyzes the current and future prospects of the glaucoma therapeutics market based on type of drug class, end user and geography.

Glaucoma Therapeutics Market: Scope and Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each by drug class, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors.

The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for drug class was calculated on the basis of prevalence of diseases, and number of people affected by the disease

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the glaucoma therapeutics market in the current and future scenario.

Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the glaucoma therapeutics market.

Glaucoma Therapeutics Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the glaucoma therapeutics market are Allergan Inc., Merck & Co., Pfizer Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals and Aerie Pharmaceuticals.

The glaucoma therapeutics market has been segmented as follows:

Glaucoma Therapeutics Market, by Drug Class

Alpha Agonist
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitor
Cholinergic
Combined Medication
Glaucoma Therapeutics Market, by End Users

Ophthalmic clinic
Hospitals
Ambulatory Surgical Centers
Glaucoma Therapeutics Market, by Geography

North America
U.S.
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
U.K.
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
India
Japan
China
Australia
New Zealand
Rest of Asia Pacific
Middle East and Africa
South Africa
Saudi Arabia
A.E.
Rest of MEA

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Glaucoma Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Class of Drug Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.4. Trends
4.5. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2014–2024
4.5.1. Market Volume Projections, 2014–2024
4.5.2. Pricing – Actuals and Projections, 2014–2024
4.5.3. Market Revenue Projections (US$ Mn)
4.6. Global Glaucoma Therapeutics Market – Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook

5. Global Glaucoma Therapeutics Market Analysis and Forecasts, By Class of Drug
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast By Class of Drug , 2014–2024
5.4.1. Prostaglandins
5.4.2. Alpha Agonist
5.4.3. Beta Blockers
5.4.4. Carbonic Anhydrase Inhibitor
5.4.5. Cholinergic
5.4.6. Combined Medication
5.5. Class of Drug Comparison Matrix
5.6. Market Attractiveness By Class of Drug

6. Global Glaucoma Therapeutics Market Analysis and Forecasts, By End Users
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast By End Users , 2014–2024
6.4.1. Ophthalmic Clinic
6.4.2. Hospitals
6.4.3. Ambulatory Surgical Centers
6.5. End Users Comparison Matrix
6.6. Market Attractiveness By End Users

7. Global Glaucoma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Policies and Regulations
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness By Country/Region

8. North America Global Glaucoma Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Price Trend Analysis
8.1.4. Key Trends
8.2. Market Value Forecast By Class of Drug , 2014–2024
8.2.1. Prostaglandins
8.2.2. Alpha Agonist
8.2.3. Beta Blockers
8.2.4. Carbonic Anhydrase Inhibitor
8.2.5. Cholinergic
8.2.6. Combined Medication
8.3. Market Value Forecast By End Users , 2014–2024
8.3.1. Ophthalmic Clinic
8.3.2. Hospitals
8.3.3. Ambulatory Surgical Centers
8.4. Market Value Forecast By Country , 2014–2024
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Class of Drug
8.5.2. By End Users
8.5.3. By Country

9. Europe Global Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market Value Forecast By Class of Drug , 2014–2024
9.2.1. Prostaglandins
9.2.2. Alpha Agonist
9.2.3. Beta Blockers
9.2.4. Carbonic Anhydrase Inhibitor
9.2.5. Cholinergic
9.2.6. Combined Medication
9.3. Market Value Forecast By End Users , 2014–2024
9.3.1. Ophthalmic Clinic
9.3.2. Hospitals
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast By Country , 2014–2024
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Class of Drug
9.5.2. By End Users
9.5.3. By Country

10. Asia Pacific Global Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market Value Forecast By Class of Drug , 2014–2024
10.2.1. Prostaglandins
10.2.2. Alpha Agonist
10.2.3. Beta Blockers
10.2.4. Carbonic Anhydrase Inhibitor
10.2.5. Cholinergic
10.2.6. Combined Medication
10.3. Market Value Forecast By End Users , 2014–2024
10.3.1. Ophthalmic Clinic
10.3.2. Hospitals
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast By Country , 2014–2024
10.4.1. Japan
10.4.2. China
10.4.3. Australia
10.4.4. New Zealand
10.4.5. India
10.4.6. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Class of Drug
10.5.2. By End Users
10.5.3. By Country

11. Latin America Global Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2. Market Value Forecast By Class of Drug , 2014–2024
11.2.1. Prostaglandins
11.2.2. Alpha Agonist
11.2.3. Beta Blockers
11.2.4. Carbonic Anhydrase Inhibitor
11.2.5. Cholinergic
11.2.6. Combined Medication
11.3. Market Value Forecast By End Users , 2014–2024
11.3.1. Ophthalmic Clinic
11.3.2. Hospitals
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast By Country , 2014–2024
11.4.1. Brazil
11.4.2. Mexico
11.5. Market Attractiveness Analysis
11.5.1. By Class of Drug
11.5.2. By End Users
11.5.3. By Country

12. Middle East & Africa Global Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2. Market Value Forecast By Class of Drug , 2014–2024
12.2.1. Prostaglandins
12.2.2. Alpha Agonist
12.2.3. Beta Blockers
12.2.4. Carbonic Anhydrase Inhibitor
12.2.5. Cholinergic
12.2.6. Combined Medication
12.3. Market Value Forecast By End Users , 2014–2024
12.3.1. Ophthalmic Clinic
12.3.2. Hospitals
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast By Country , 2014–2024
12.4.1. South Africa
12.4.2. UAE
12.4.3. Saudi Arabia
12.5. Market Attractiveness Analysis
12.5.1. By Class of Drug
12.5.2. By End Users
12.5.3. By Country

13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis By Company (2015)
13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Allergan Inc.
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. SWOT Analysis
13.3.1.5. Strategic Overview
13.3.2. Merck & Co.
13.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Financial Overview
13.3.2.3. Product Portfolio
13.3.2.4. SWOT Analysis
13.3.2.5. Strategic Overview
13.3.3. Novartis AG
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Financial Overview
13.3.3.3. Product Portfolio
13.3.3.4. SWOT Analysis
13.3.3.5. Strategic Overview
13.3.4. Pfizer Inc.
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Financial Overview
13.3.4.3. Product Portfolio
13.3.4.4. SWOT Analysis
13.3.4.5. Strategic Overview
13.3.5. Santen Pharmaceuticals
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Financial Overview
13.3.5.3. Product Portfolio
13.3.5.4. SWOT Analysis
13.3.5.5. Strategic Overview
13.3.6. Valeant Pharmaceuticals Inc.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Financial Overview
13.3.6.3. Product Portfolio
13.3.6.4. SWOT Analysis
13.3.6.5. Strategic Overview
13.3.7. Aerie Pharmaceuticals Inc.
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Financial Overview
13.3.7.3. Product Portfolio
13.3.7.4. SWOT Analysis
13.3.7.5. Strategic Overview

List of Tables

Table 1 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 2 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 3 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 4 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 5 North America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 6 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 7 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 8 Europe Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 9 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 10 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 11 Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 12 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 14 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15 Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 16 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18 Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 19 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024